Skip to main content
Brixadi Coupon - Brixadi monthly of 96mg/0.27ml syringe

Brixadi

buprenorphine
Used for Opioid Dependence

Brixadi (buprenorphine) is an injection given under the skin by a healthcare professional for moderate to severe opioid use disorder. It's typically given along with counseling, as well as social and emotional support. Brixadi (buprenorphine) is conveniently given once per week or once per month, but it's only for people who've previously tolerated another form of buprenorphine (e.g., buprenorphine (Zubsolv) film or buprenorphine (Subutex)). Some side effects of Brixadi (buprenorphine) include injection site reactions (e.g., pain or swelling), headache, and constipation.

Reviewed by:Last reviewed on July 31, 2023
basics-icon

What is Brixadi (buprenorphine)?

What is Brixadi (buprenorphine) used for?

How Brixadi (buprenorphine) works

Brixadi (buprenorphine) is a partial opioid agonist. It works by attaching to the same receptors in the brain as opioids, but less strongly. It helps ease cravings and lower the risk for withdrawal symptoms, but shouldn't cause the same "high" as opioids.

When Brixadi (buprenorphine) is injected into your body, it turns into a solid gel (called a depot) under the skin. This gel then slowly releases a steady amount of medication throughout the month.

Drug facts

Common BrandsBrixadi
Drug ClassOpioid partial agonist
Controlled Substance ClassificationSchedule III
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
warnings-icon

Risks and warnings for Brixadi (buprenorphine)

Brixadi (buprenorphine) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

Not for intravenous (IV) administration

Black Box Warning Brixadi (buprenorphine) should only be given as an injection under the skin (subcutaneous). It should never be given into the veins (intravenous, or IV) because it can cause serious harm, including death.

Black Box Warning Brixadi (buprenorphine) is part of the FDA's Risk Evaluation and Mitigation Strategy (REMS) program because of its risk of serious harm if given as an IV. Under the REMS program, your provider(s) will be trained on how to inject Brixadi (buprenorphine) properly.

Risk for addiction, misuse, and abuse

Take Brixadi (buprenorphine) only as directed by your provider. This medication is a controlled substance because it does have a risk for addiction and misuse.

Dangerously slow breathing (respiratory depression)

  • Risk factors: Taking medications that can cause slow breathing | Drinking alcohol | Medical conditions that cause breathing problems (e.g., COPD, asthma)

Brixadi (buprenorphine) can cause dangerously slow breathing, which can be life-threatening. This can happen at any time, even with recommended doses. Your risk is higher if you're taking medications that can slow breathing (e.g., benzodiazepines, opioids, sedatives), drinking alcohol, or have breathing problems (e.g., COPD, asthma). Your provider will likely prescribe you naloxone (Narcan) that you should carry with you at all times in case you experience breathing problems and need to reverse the effects of Brixadi (buprenorphine). If you or your loved one notice you have trouble breathing or have bluish-colored lips, fingers, or toes, give yourself naloxone (Narcan) if you have it and call 911 to get medical help right away.

Harm to newborns

  • Risk factors: Taking Brixadi (buprenorphine) during pregnancy

If you take Brixadi (buprenorphine) during pregnancy, you can pass the medication to your unborn baby. Long-term use during pregnancy can cause your unborn baby to become dependent on opioids and cause withdrawal symptoms at birth. Symptoms of withdrawal can include high-pitched crying, poor feeding and sucking behavior, and seizures. This condition can be life-threatening if not recognized and treated in time. Make sure to tell your provider if you've received Brixadi (buprenorphine) during pregnancy. Providers who are experts in this area will know how to treat your newborn and will make sure your baby gets the care they need once they're born.

Low adrenal hormone levels

  • Risk factors: Taking Brixadi (buprenorphine) for longer than 1 month

Though rare, taking opioids, like Brixadi (buprenorphine), can cause your adrenal hormone levels to drop. This is more likely to happen after taking opioids for longer than 1 month. Symptoms include nausea, vomiting, not feeling hungry, tiredness, dizziness, and weakness. Let your provider know right away if you experience these symptoms because you might need to stop Brixadi (buprenorphine) and be treated with corticosteroids.

Risk of withdrawal symptoms

Suddenly stopping Brixadi (buprenorphine) might lead to symptoms of opioid withdrawal. Don't suddenly stop taking Brixadi (buprenorphine) without first talking with your provider. If you want to stop this medication, your provider can help you do so safely by lowering your dose slowly over time.

Liver damage

  • Risk factors: History of liver damage | Hepatitis B or C infection | Taking other medications that can cause liver damage | Injection drug use

There have been reports of liver damage in people who take Brixadi (buprenorphine). This medication isn't recommended for you if you already have liver problems. Your provider might ask that you get blood tests before and during Brixadi (buprenorphine) treatment to make sure your liver is healthy. Let your provider know if you experience symptoms of liver problems such as feeling tired, nausea, dark urine, pale stool, and yellowing of the whites of the eyes and skin.

Risks with treatment for pain

If you need to take pain medications for whatever reason, make sure to let your provider know that you're already taking Brixadi (buprenorphine). Since Brixadi (buprenorphine) is an opioid, it's best to start with non-opioid pain medications first. This is because opioid medications might not work as well for you and treatment can put you at risk for opioid toxicity and side effects, such as trouble breathing. If you need opioid therapy, you'll only be able to receive care under a provider's supervision.

Not for use in people who haven't taken opioids before

There have been reports of deaths of people who haven't taken opioids before and received 2 mg of buprenorphine. Brixadi (buprenorphine) is only for people who are currently taking opioids.

Life-threatening heart rhythm problems (QT prolongation)

  • Risk factors: Heartbeat or heart rhythm problems | Taking medications that affect your heartbeat or heart rhythm | Electrolytes (body salts) not in balance

Buprenorphine can cause QT prolongation, a potentially life-threatening heart rhythm problem. Your risk for these problems is higher if you already have heart problems or are taking other medications that cause QT prolongation that can change your heartbeat and heart rhythm, such as amiodarone (Pacerone), beta-blockers, and moxifloxacin (Avelox). Make sure to tell your provider about all the medications you're taking and also check with them before you start any new medications. If you feel symptoms of heart problems, such as pounding chest, trouble breathing, feeling faint or lightheaded, or chest pain while taking Brixadi (buprenorphine), call 911 right away.

side-effects-icon

Side effects of Brixadi (buprenorphine)

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

  • Injection site reactions, including pain, itching, and swelling (up to 21%)
  • Headache (8%)
  • Constipation (8%)
  • Nausea (7%)
  • Difficulty sleeping (6%)
  • Urinary tract infection (5%)

Less Common Side Effects

  • Upper respiratory tract infection
  • Vomiting
  • Diarrhea
  • Joint pain
  • Anxiety

Brixadi (buprenorphine) serious side effects

Contact your healthcare provider immediately if you experience any of the following.

  • Opioid withdrawal: suicidal thoughts, anxiety, restlessness, runny nose, yawning, sweating, chills, wide pupils, irritability
  • Dangerously slow breathing: trouble breathing; bluish-colored lips, fingers, or toes
  • Serious allergic reactions: rash, hives, shortness of breath, low blood pressure, fast heartbeat, dizziness, flushing (feeling warm all of a sudden), fatigue
  • Heart rhythm problems: chest pounding, fluttering in the chest, difficulty breathing, chest pain, feeling faint or lightheaded

Source: DailyMed

The following Brixadi (buprenorphine) side effects have also been reported

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • CNS depression—slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, trouble staying awake
  • Heart rhythm changes—fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, trouble breathing
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue
  • Low adrenal gland function—nausea, vomiting, loss of appetite, unusual weakness or fatigue, dizziness
  • Low blood pressure—dizziness, feeling faint or lightheaded, blurry vision
  • Urinary tract infection (UTI)—burning when passing urine, passing frequent small amounts of urine, bloody or cloudy urine, pain in the lower back or sides

Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):

pros-and-cons-icon

Pros and cons of Brixadi (buprenorphine)

Pros

  • Works well to treat moderate to severe opioid use disorder
  • Given once per week or once per month
  • Only trained healthcare providers who are registered with the REMS program can give you Brixadi (buprenorphine), to make sure this medication is as safe for you as possible

Cons

  • Injection only
  • Needs to go to the provider's office regularly to receive injection
  • Has a lot of potential risks and side effects, such as breathing problems and sleepiness
pharmacist-tips-icon

Pharmacist tips for Brixadi (buprenorphine)

pharmacist
  • Make sure to mark your appointments on your calendar for when you need to see your provider and receive your Brixadi (buprenorphine) doses. These appointments are important to discuss how treatment is going for you and make sure you don't miss any doses.
  • If you miss a dose of Brixadi (buprenorphine), contact your provider's office as soon as possible. There's a risk that missed doses can lead you to experience symptoms of opioid withdrawal, including muscle pain, stomach cramps, and diarrhea.
  • You might notice a lump at the injection site after receiving Brixadi (buprenorphine). This is the solid gel that'll slowly release the medication over time. As the medication is released, the lump will get smaller. Don't rub the lump.
  • Brixadi (buprenorphine) levels can be detected in your blood and urine for a long time after you've stopped taking it. If you're required to undergo a drug test, make sure to notify the drug-test center that you previously received Brixadi (buprenorphine).
  • Make sure to tell your provider about all of the medications you're taking before starting Brixadi (buprenorphine). Don't start any new medications while you're in the middle of Brixadi (buprenorphine) treatment without talking to your provider first. Taking Brixadi (buprenorphine) together with benzodiazepines, opioids, sedatives, or alcohol can worsen the side effects of Brixadi (buprenorphine) (e.g., slow breathing rate, severe sleepiness), which can be life-threatening.
  • Let your provider know if you're taking any mood medications, such as fluoxetine (Prozac) or citalopram (Celexa). Taking with mood medications that raise serotonin levels can raise your risk of a rare, but serious, side effect called serotonin syndrome. Symptoms of serotonin syndrome include sweating, fast heart rate, and trouble sleeping.
  • Don't stop taking Brixadi (buprenorphine) without talking to your provider first because they'll need to lower your dose slowly before stopping it completely so you don't get any withdrawal symptoms (e.g., suicidal thoughts, anxiety, restlessness, runny nose, yawning, sweating, chills, wide pupils, irritability). Since Brixadi (buprenorphine) is long-acting, withdrawal symptoms can be seen 2 to 5 months after the last injection.
  • Brixadi (buprenorphine) can make you sleepy and dizzy, which can affect your ability to focus, think, or react. Don't drive or do anything requiring your full attention, especially during the first few days following treatment or a change in your dose, until you know how this medication affects you.
  • Let your provider know right away if you have a head injury while receiving treatment with Brixadi (buprenorphine). Because taking buprenorphine might raise the pressure of fluids inside your brain, there's a risk that head trauma can be particularly dangerous.
faq-icon

Common questions about Brixadi (buprenorphine)

Both Brixadi and Sublocade are buprenorphine medications that are injected under the skin by a healthcare provider. A major difference is Brixadi (buprenorphine) can be given in the buttock, thigh, stomach, or upper arm, whereas Sublocade can only be given in the stomach. Another difference is Brixadi (buprenorphine) can be given once per week or once per month, whereas Sublocade is just given once per month.

People currently being treated with a transmucosal (under the tongue or in the cheek) form of buprenorphine (e.g., buprenorphine (Zubsolv) film, buprenorphine (Subutex), etc.) can receive Brixadi (buprenorphine) weekly or monthly. But people who haven't been on any form of buprenorphine must first receive a 4 mg test-dose of transmucosal buprenorphine. If the person tolerates that, they can start getting Brixadi (buprenorphine) once weekly. After a certain amount of time of weekly injections, your provider can decide if you should continue receiving Brixadi (buprenorphine) weekly or if you can change to once-monthly dosing.

Since Brixadi (buprenorphine) can put you at risk for serious harm or death if injected into the veins, it's only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Brixadi REMS program. You and your provider must be registered with the REMS program, and your provider must be trained on the proper way to inject Brixadi (buprenorphine). This is to make sure the medication is distributed and taken under the safest conditions possible for you.

While Brixadi (buprenorphine) is used to treat opioid use disorder, it can also cause misuse and dependence if not used properly, which can lead to addiction. Because of this risk, Brixadi (buprenorphine) is a controlled (Schedule III) medication. If you have any questions or concerns, talk with your provider.

No, unlike some other buprenorphine-containing medications, Brixadi (buprenorphine) isn't something you can pick up at the pharmacy and give to yourself at home. Brixadi (buprenorphine) is only available under a REMS program and must be given by a healthcare provider.

educational-icon

How to save using GoodRx

Compare Prices
1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
Select your free coupon
2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
Show coupon to your pharmacist
3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
Get free couponLearn more
dosage-icon

Brixadi (buprenorphine) dosage

Typical dosage for Brixadi (buprenorphine)

If you've never taken buprenorphine before, your provider will give you buprenorphine 4 mg, either under the tongue or absorbed through the cheek (e.g., buprenorphine (Zubsolv) film or buprenorphine (Subutex)), as a test dose.

  • People not currently taking buprenorphine: When you first start treatment, your provider will determine your dose of Brixadi (buprenorphine) by giving you small doses of Brixadi (buprenorphine) over the course of a week to see how you respond. The typical maintenance dose of Brixadi (buprenorphine) ranges from 24 mg to 32 mg injected under the skin once a week.
  • People switching from transmucosal buprenorphine to Brixadi (buprenorphine): Your provider will determine your dose of Brixadi (buprenorphine) based on how much transmucosal buprenorphine you've been taking. The typical dose of Brixadi (buprenorphine) ranges from 8 mg to 32 mg injected under the skin once a week, to 64 mg to 128 mg injected once a month.
contraindications-icon

Brixadi (buprenorphine) contraindications

Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Brixadi (buprenorphine) will not be safe for you to take.

  • Allergy to any buprenorphine product
  • People who haven't taken opioids before
alternatives-icon

What are alternatives to Brixadi (buprenorphine)?

There are a number of medications that your doctor can prescribe in place of Brixadi (buprenorphine). Compare a few possible alternatives below.
Brixadi (buprenorphine)
Used for:
Used for:
images-icon

Brixadi (buprenorphine) images

yellow - Brixadi 96mg/0.27mL Monthly Extended-Release Solution for Injection
This medicine is Yellow Syringe.yellow - Brixadi 96mg/0.27mL Monthly Extended-Release Solution for Injection

Get savings updates for Brixadi (buprenorphine)

Receive price alerts, news, and other messages from GoodRx about Brixadi (buprenorphine) and other healthcare topics and relevant savings offers.

By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men's health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.

References

Best studies we found

Al-Khatib, S. M., e tal. (2003). What clinicians should know about the QT interval. Journal of the American Medical Association.

Braeburn, Inc. (2023). Brixadi- buprenorphine injection [package insert]. DailyMed.

Braeburn, Inc. (n.d.). Welcome to the Brixadi REMS (risk evaluation and mitigation strategy).

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?